» Articles » PMID: 35757415

An Overview on Different L-Thyroxine (l-T) Formulations and Factors Potentially Influencing the Treatment of Congenital Hypothyroidism During the First 3 Years of Life

Overview
Specialty Endocrinology
Date 2022 Jun 27
PMID 35757415
Authors
Affiliations
Soon will be listed here.
Abstract

Congenital hypothyroidism (CH) is a relatively frequent congenital endocrine disorder, caused by defective production of thyroid hormones (THs) at birth. Because THs are essential for the development of normal neuronal networks, CH is also a common preventable cause of irreversible intellectual disability (ID) in children. Prolonged hypothyroidism, particularly during the THs-dependent processes of brain development in the first years of life, due to delays in diagnosis, inadequate timing and dosing of levothyroxine (l-thyroxine or l-T), the non-compliance of families, incorrect follow-up and the interference of foods, drugs and medications affecting the absorption of l-T, may be responsible for more severe ID. In this review we evaluate the main factors influencing levels of THs and the absorption of l-T in order to provide a practical guide, based on the existing literature, to allow optimal follow-up for these patients.

Citing Articles

Comparison between Liquid and Tablet Formulations in the Treatment of Congenital Hypothyroidism up to 3 Years of Age: The First Italian Study.

Ortolano R, Cantarelli E, Baronio F, Assirelli V, Candela E, Mastrangelo C Children (Basel). 2024; 11(9).

PMID: 39334669 PMC: 11430788. DOI: 10.3390/children11091136.


Management of Neonatal Isolated and Combined Growth Hormone Deficiency: Current Status.

Stagi S, Tufano M, Chiti N, Cerutti M, Li Pomi A, Aversa T Int J Mol Sci. 2023; 24(12).

PMID: 37373261 PMC: 10299208. DOI: 10.3390/ijms241210114.

References
1.
Heyerdahl S, Oerbeck B . Congenital hypothyroidism: developmental outcome in relation to levothyroxine treatment variables. Thyroid. 2003; 13(11):1029-38. DOI: 10.1089/105072503770867200. View

2.
Salerno M, Micillo M, Di Maio S, Capalbo D, Ferri P, Lettiero T . Longitudinal growth, sexual maturation and final height in patients with congenital hypothyroidism detected by neonatal screening. Eur J Endocrinol. 2001; 145(4):377-83. DOI: 10.1530/eje.0.1450377. View

3.
Filippi L, Pezzati M, Cecchi A, Poggi C . Dopamine infusion: a possible cause of undiagnosed congenital hypothyroidism in preterm infants. Pediatr Crit Care Med. 2006; 7(3):249-51. DOI: 10.1097/01.PCC.0000216680.22950.D9. View

4.
Centanni M . Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches. Endocrine. 2012; 43(1):8-9. DOI: 10.1007/s12020-012-9814-9. View

5.
Rovet J, Ehrlich R . Long-term effects of L-thyroxine therapy for congenital hypothyroidism. J Pediatr. 1995; 126(3):380-6. DOI: 10.1016/s0022-3476(95)70452-3. View